Three-Year Patient-Related and Stent-Related Outcomes of Second-Generation Everolimus-Eluting Xience V Stents Versus Zotarolimus-Eluting Resolute Stents in Real-World Practice (from the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Joo Myung | - |
dc.contributor.author | Park, Kyung Woo | - |
dc.contributor.author | Han, Jung-Kyu | - |
dc.contributor.author | Yang, Han-Mo | - |
dc.contributor.author | Kang, Hyun-Jae | - |
dc.contributor.author | Koo, Bon-Kwon | - |
dc.contributor.author | Bae, Jang-Whan | - |
dc.contributor.author | Woo, Sung-Il | - |
dc.contributor.author | Park, Jin Sik | - |
dc.contributor.author | Jin, Dong-Kyu | - |
dc.contributor.author | Jeon, Dong Woon | - |
dc.contributor.author | Oh, Seok Kyu | - |
dc.contributor.author | Park, Jong-Seon | - |
dc.contributor.author | Kim, Doo-Il | - |
dc.contributor.author | Hyon, Min Su | - |
dc.contributor.author | Jeon, Hui-Kyung | - |
dc.contributor.author | Lim, Do-Sun | - |
dc.contributor.author | Kim, Myeong-Gon | - |
dc.contributor.author | Rha, Seung-Woon | - |
dc.contributor.author | Her, Sung-Ho | - |
dc.contributor.author | Hwang, Jin-Yong | - |
dc.contributor.author | Kim, Sanghyun | - |
dc.contributor.author | Choi, Young Jin | - |
dc.contributor.author | Kang, Jin Ho | - |
dc.contributor.author | Moon, Keon-Woong | - |
dc.contributor.author | Jang, Yangsoo | - |
dc.contributor.author | Kim, Hyo-Soo | - |
dc.date.accessioned | 2021-09-05T03:07:22Z | - |
dc.date.available | 2021-09-05T03:07:22Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-11-01 | - |
dc.identifier.issn | 0002-9149 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/96810 | - |
dc.description.abstract | Long-term outcomes are imperative to confirm safety of drug-eluting stents. There have been 2 randomized controlled trials comparing everolimus-eluting stents (EESs) and Resolute zotarolimus-eluting stents (ZES-Rs). To date, long-term clinical outcomes of these stents were limited to only 1 report, which has recently reported 4-year comparisons of these stents. Therefore, more evidence is needed regarding long-term clinical outcomes of the second-generation stents. This study compared the long-term clinical outcomes of EES with ZES-R in "all-corner" cohorts up to 3-year follow-up. The EXCELLENT and RESOLUTE-Korea registries prospectively enrolled 3,056 patients treated with EES and 1,998 with ZES-R, respectively, without exclusions. Stent-related composite outcomes (target lesion failure). and patient-related composite events up to 3-year follow-up were compared in crude and propensity score matched analyses. Of 5,054 patients, 3,830 patients (75.8%) had off-label indication (2,217 treated with EES and 1,613 treated with ZES-R). The stent-related outcome (189 [6.2%] vs 127 [6.4%], p = 0.812) and the patient-related outcome (420 [13.7%] vs 250 [12.5%], p = 0.581) did not differ between EES and ZES-R, respectively, at 3 years, which was corroborated by similar results from the propensity score matched cohort (hazard ratio [HR] 0.92, 95% confidence interval [CI] 0.70 to 1.20, p = 0.523 and 0.85, 95% CI 0.70 to 1.02, p = 0.081, for stent- and patient-related outcomes, respectively). The rate of definite or probable stent thrombosis up to 3 years (22 [0.7%] vs 10 [0.5%], p = 0.370) was also similar. The rate of very late definite or probable stent thrombosis was very low and comparable between the 2 stents (3 [0.1%] vs 1 [0.1%], p = 0.657). In multivariate analysis, chronic. renal failure (adjusted FIR 3.615, 95% CI 2.440 to 5.354, p < 0.001) and off-label indication (adjusted HR 1.782, 95% CI 1.169 to 2.718, p = 0.007) were the strongest predictors of target lesion failure at 3 years. In conclusion, both stents showed comparable safety and efficacy at 3-year follow-up in this robust real-world registry with unrestricted use of EES and ZES-R. Overall incidences of target lesion failure and definite stent thrombosis, including very late stent thrombosis, were low, even in the patients with off-label indications, suggesting excellent long-term safety and sustained efficacy of both types of second-generation drug-eluting stents. (C) 2014 Elsevier Inc. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC | - |
dc.subject | PERCUTANEOUS CORONARY INTERVENTION | - |
dc.subject | 2-YEAR FOLLOW-UP | - |
dc.subject | DIABETES-MELLITUS | - |
dc.subject | TRIAL | - |
dc.subject | REVASCULARIZATION | - |
dc.subject | DEFINITIONS | - |
dc.subject | DISEASE | - |
dc.title | Three-Year Patient-Related and Stent-Related Outcomes of Second-Generation Everolimus-Eluting Xience V Stents Versus Zotarolimus-Eluting Resolute Stents in Real-World Practice (from the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries) | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lim, Do-Sun | - |
dc.contributor.affiliatedAuthor | Rha, Seung-Woon | - |
dc.identifier.doi | 10.1016/j.amjcard.2014.07.065 | - |
dc.identifier.scopusid | 2-s2.0-84908069051 | - |
dc.identifier.wosid | 000343960000007 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF CARDIOLOGY, v.114, no.9, pp.1329 - 1338 | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF CARDIOLOGY | - |
dc.citation.title | AMERICAN JOURNAL OF CARDIOLOGY | - |
dc.citation.volume | 114 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 1329 | - |
dc.citation.endPage | 1338 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | PERCUTANEOUS CORONARY INTERVENTION | - |
dc.subject.keywordPlus | 2-YEAR FOLLOW-UP | - |
dc.subject.keywordPlus | DIABETES-MELLITUS | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | REVASCULARIZATION | - |
dc.subject.keywordPlus | DEFINITIONS | - |
dc.subject.keywordPlus | DISEASE | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.